Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1a/1b Study of BG-68501, a Selective CDK2 Inhibitor, in Participants With Advanced Solid Tumors

NCT06257264 is registered in ClinicalTrials.gov with BeiGene as lead sponsor.

NCT NCT06257264
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06257264 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1a/1b Study of BG-68501, a Selective CDK2 Inhibitor, in Participants With Advanced Solid Tumors
Lead sponsor
BeiGene
Phase
Phase 1
Overall status
Active, not recruiting
Start date
March 11, 2024
Completion date
August 31, 2026
Enrollment
103 (actual)
Sites
24

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumor, bladder cancer, breast cancer, endometrial cancer, gastric cancer, gastroesophageal cancer, hormone receptor positive her-2 negative breast cancer, hormone-receptor-positive breast cancer, ovarian cancer, prostate cancer, small cell lung cancer, tnbc - triple-negative breast cancer